Hoth Therapeutics, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a HOTH research report →
Companywww.hoththerapeutics.com
Hoth Therapeutics, Inc. , a clinical-stage biopharmaceutical company, focuses on developing therapies for unmet medical needs. It is involved in the development of HT-001, a topical formulation for the treatment of patients with rash and skin disorders associated with initial and repeat courses of tyrosine kinase epidermal growth factor receptor inhibitor therapy; HT-KIT to treat mast-cell derived cancers and anaphylaxis; HT-ALZ for the treatment and/or prevention of Alzheimer's or other neuroinflammatory diseases; HT-003 to treat inflammatory bowel diseases, as well as acne and psoriasis; HT-004 for treatment of asthma and allergies using inhalational administration; HT-006 to treat lung diseases resulting from bacterial infections; and HT-002, a novel peptide for treating COVID-19.
- CEO
- Robb Knie
- IPO
- 2019
- Employees
- 2
- HQ
- New York City, NY, US
Price Chart
Valuation
- Market Cap
- $8.02M
- P/E
- -0.82
- P/S
- 0.00
- P/B
- 2.30
- EV/EBITDA
- -0.34
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -165.25%
- ROIC
- -277.16%
Growth & Income
- Revenue
- $0 · 0.00%
- Net Income
- $-12,469,302 · -52.28%
- EPS
- $-0.90 · 29.69%
- Op Income
- $-11,110,849
- FCF YoY
- -40.49%
Performance & Tape
- 52W High
- $2.12
- 52W Low
- $0.49
- 50D MA
- $0.76
- 200D MA
- $1.12
- Beta
- 0.58
- Avg Volume
- 2.75M
Get TickerSpark's AI analysis on HOTH
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Aug 27, 25 | Knie Robb | other | 800,000 |
| Aug 28, 25 | Knie Robb | other | 310,744 |
| May 8, 25 | Camarra Christopher Michael | other | 0 |
| Jan 14, 25 | Knie Robb | other | 93,000 |
| Jan 14, 25 | Knie Robb | other | 7,000 |
| Jan 14, 25 | Springer Graig | other | 70,000 |
| Aug 19, 24 | Pavell Jeff | other | 25,000 |
| Aug 19, 24 | Springer Graig | other | 48,000 |
| Aug 19, 24 | Sarnoff David | other | 25,000 |
| Aug 19, 24 | Springer Graig | other | 25,000 |
Our HOTH Coverage
We haven't published any research on HOTH yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate HOTH Report →